ULBI vs. STEM, GWH, NVX, ELVA, CBAT, FLUX, DFLI, SES, COMM, and CANG
Should you be buying Ultralife stock or one of its competitors? The main competitors of Ultralife include Stem (STEM), ESS Tech (GWH), NOVONIX (NVX), Electrovaya (ELVA), CBAK Energy Technology (CBAT), Flux Power (FLUX), Dragonfly Energy (DFLI), SES AI (SES), CommScope (COMM), and Cango (CANG). These companies are all part of the "computer and technology" sector.
Ultralife (NASDAQ:ULBI) and Stem (NYSE:STEM) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
30.7% of Ultralife shares are owned by institutional investors. Comparatively, 61.6% of Stem shares are owned by institutional investors. 42.7% of Ultralife shares are owned by insiders. Comparatively, 10.2% of Stem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Ultralife received 233 more outperform votes than Stem when rated by MarketBeat users. Likewise, 71.51% of users gave Ultralife an outperform vote while only 41.18% of users gave Stem an outperform vote.
Ultralife has higher earnings, but lower revenue than Stem. Stem is trading at a lower price-to-earnings ratio than Ultralife, indicating that it is currently the more affordable of the two stocks.
In the previous week, Stem had 1 more articles in the media than Ultralife. MarketBeat recorded 2 mentions for Stem and 1 mentions for Ultralife. Ultralife's average media sentiment score of 1.95 beat Stem's score of 0.18 indicating that Ultralife is being referred to more favorably in the media.
Ultralife has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Stem has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Ultralife has a net margin of 6.19% compared to Stem's net margin of -40.03%. Ultralife's return on equity of 10.31% beat Stem's return on equity.
Ultralife currently has a consensus price target of $13.00, suggesting a potential upside of 15.56%. Stem has a consensus price target of $4.77, suggesting a potential upside of 275.83%. Given Stem's higher probable upside, analysts clearly believe Stem is more favorable than Ultralife.
Summary
Ultralife beats Stem on 12 of the 18 factors compared between the two stocks.
Get Ultralife News Delivered to You Automatically
Sign up to receive the latest news and ratings for ULBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ULBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultralife Competitors List
Related Companies and Tools
